Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Bio:

TUM Professoren - Daumer_Martin

Prof. Daumer studied physics at the Ludwig-Maximilians-Universität München (Diplom 1990: “The Phase Operator in Quantum Optics”), where he received his doctorate in mathematics in 1995 for his dissertation on “Scattering Theory from the Perspective of Bohmian Mechanics.” After joining the TUM School of Medicine (Institute for Medical Statistics and Epidemiology, Klinikum rechts der Isar) and extensive research in “Online Monitoring in Medicine,” he co-founded the company Trium Analysis Online GmbH (www.trium.de) in 2000 and a year later the non-profit research institute Sylvia Lawry Centre for Multiple Sclerosis Research e.V. (www.thehumanmotioninstitute.org).

Prof. Daumer's current research focuses on medical monitoring, wearables and clinical studies. “CTG Online” is a medical device for the global monitoring of maternity wards, while a new generation of target parameters for clinical studies based on the Ian MacDonald Database and the wearable www.actibelt.com is currently under development in cooperation with regulatory authorities (EMA, FDA).

 

Abstract:

This talk will be about the links between 

a) The development of a device-agnostic system for electronic fetal monitoring, including physiological models and algorithms, biostatistical analyses of large data sets, guidelines and modern tools for telemonitoring.   

b) The extension to the general concept of mobile monitoring of human biosignals with wearables and the subsequent reduction to a waist-worn multi-sensor system and data platform (my focus is on www.actibelt.com). 

c) The application of some of the methodology and technology to e-clinical trials, using real world & registry data for research & regulatory decision making by EMA/FDA. The focus will be on the use of wearables to derive "real world walking speed" as

a new outcome measure for Multiple Sclerosis and related diseases.